Daclatasvir plus peginterferon and ribavirin is noninferior to peginterferon and ribavirin alone, and reduces the duration of treatment for HCV genotype 2 or 3 infection.
Identifieur interne : 002D47 ( PubMed/Checkpoint ); précédent : 002D46; suivant : 002D48Daclatasvir plus peginterferon and ribavirin is noninferior to peginterferon and ribavirin alone, and reduces the duration of treatment for HCV genotype 2 or 3 infection.
Auteurs : Gregory J. Dore [Australie] ; Eric Lawitz [États-Unis] ; Christophe Hézode [France] ; Stephen D. Shafran [Canada] ; Alnoor Ramji [Canada] ; Harvey A. Tatum [États-Unis] ; Gloria Taliani [Italie] ; Albert Tran [France] ; Maurizia R. Brunetto [Italie] ; Serena Zaltron [Italie] ; Simone I. Strasser [Australie] ; Nina Weis [Danemark] ; Wayne Ghesquiere [Canada] ; Samuel S. Lee [Canada] ; Dominique Larrey [France] ; Stanislas Pol [France] ; Hugh Harley [Australie] ; Jacob George [Australie] ; Scott K. Fung [Canada] ; Victor De Lédinghen [France] ; Peggy Hagens [Belgique] ; Fiona Mcphee [États-Unis] ; Dennis Hernandez [États-Unis] ; David Cohen [États-Unis] ; Elizabeth Cooney [États-Unis] ; Stephanie Noviello [États-Unis] ; Eric A. Hughes [États-Unis]Source :
- Gastroenterology [ 1528-0012 ] ; 2015.
Descripteurs français
- KwdFr :
- ARN viral (analyse), Adolescent, Adulte, Adulte d'âge moyen, Antiviraux (usage thérapeutique), Association de médicaments, Femelle, Génotype, Hepacivirus (), Humains, Hépatite C chronique (traitement médicamenteux), Hépatite C chronique (virologie), Imidazoles (administration et posologie), Imidazoles (effets indésirables), Interféron alpha (administration et posologie), Interféron alpha (effets indésirables), Interféron alpha (usage thérapeutique), Mâle, Méthode en double aveugle, Polyéthylène glycols (administration et posologie), Polyéthylène glycols (effets indésirables), Polyéthylène glycols (usage thérapeutique), Protéines recombinantes (administration et posologie), Protéines recombinantes (effets indésirables), Protéines recombinantes (usage thérapeutique), Ribavirine (administration et posologie), Ribavirine (effets indésirables), Ribavirine (usage thérapeutique), Sujet âgé.
- MESH :
- administration et posologie : Imidazoles, Interféron alpha, Polyéthylène glycols, Protéines recombinantes, Ribavirine.
- analyse : ARN viral.
- effets indésirables : Imidazoles, Interféron alpha, Polyéthylène glycols, Protéines recombinantes, Ribavirine.
- traitement médicamenteux : Hépatite C chronique.
- usage thérapeutique : Antiviraux, Interféron alpha, Polyéthylène glycols, Protéines recombinantes, Ribavirine.
- virologie : Hépatite C chronique.
- Adolescent, Adulte, Adulte d'âge moyen, Association de médicaments, Femelle, Génotype, Hepacivirus, Humains, Mâle, Méthode en double aveugle, Sujet âgé.
English descriptors
- KwdEn :
- Adolescent, Adult, Aged, Antiviral Agents (therapeutic use), Double-Blind Method, Drug Therapy, Combination, Female, Genotype, Hepacivirus (classification), Hepatitis C, Chronic (drug therapy), Hepatitis C, Chronic (virology), Humans, Imidazoles (administration & dosage), Imidazoles (adverse effects), Interferon-alpha (administration & dosage), Interferon-alpha (adverse effects), Interferon-alpha (therapeutic use), Male, Middle Aged, Polyethylene Glycols (administration & dosage), Polyethylene Glycols (adverse effects), Polyethylene Glycols (therapeutic use), RNA, Viral (analysis), Recombinant Proteins (administration & dosage), Recombinant Proteins (adverse effects), Recombinant Proteins (therapeutic use), Ribavirin (administration & dosage), Ribavirin (adverse effects), Ribavirin (therapeutic use).
- MESH :
- chemical , administration & dosage : Imidazoles, Interferon-alpha, Polyethylene Glycols, Recombinant Proteins, Ribavirin.
- chemical , adverse effects : Imidazoles, Interferon-alpha, Polyethylene Glycols, Recombinant Proteins, Ribavirin.
- chemical , analysis : RNA, Viral.
- chemical , therapeutic use : Antiviral Agents, Interferon-alpha, Polyethylene Glycols, Recombinant Proteins, Ribavirin.
- classification : Hepacivirus.
- drug therapy : Hepatitis C, Chronic.
- virology : Hepatitis C, Chronic.
- Adolescent, Adult, Aged, Double-Blind Method, Drug Therapy, Combination, Female, Genotype, Humans, Male, Middle Aged.
Abstract
Twenty-four weeks of treatment with peginterferon and ribavirin for chronic hepatitis C virus (HCV) genotype 2 or 3 infection produces a sustained virologic response (SVR) in 70%-80% of patients. We performed a randomized, double-blind, phase 2b study to assess whether adding daclatasvir, a nonstructural protein 5A (NS5A) inhibitor that is active against these genotypes, improves efficacy and shortens therapy.
DOI: 10.1053/j.gastro.2014.10.007
PubMed: 25311593
Affiliations:
- Australie, Belgique, Canada, Danemark, France, Italie, États-Unis
- Alberta, Connecticut, Languedoc-Roussillon, Latium, New Jersey, Nouvelle-Galles du Sud, Occitanie (région administrative), Oklahoma, Provence-Alpes-Côte d'Azur, Texas, Toscane, Île-de-France
- Calgary, Créteil, Montpellier, Nice, Paris, Pise, Rome, Sydney
- Université Paris-Descartes, Université de Calgary
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:25311593Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Daclatasvir plus peginterferon and ribavirin is noninferior to peginterferon and ribavirin alone, and reduces the duration of treatment for HCV genotype 2 or 3 infection.</title>
<author><name sortKey="Dore, Gregory J" sort="Dore, Gregory J" uniqKey="Dore G" first="Gregory J" last="Dore">Gregory J. Dore</name>
<affiliation wicri:level="3"><nlm:affiliation>Kirby Institute, University of New South Wales and St Vincent's Hospital, Sydney, Australia. Electronic address: gdore@kirby.unsw.edu.au.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Kirby Institute, University of New South Wales and St Vincent's Hospital, Sydney</wicri:regionArea>
<placeName><settlement type="city">Sydney</settlement>
<region type="état">Nouvelle-Galles du Sud</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Lawitz, Eric" sort="Lawitz, Eric" uniqKey="Lawitz E" first="Eric" last="Lawitz">Eric Lawitz</name>
<affiliation wicri:level="2"><nlm:affiliation>The Texas Liver Institute, University of Texas Health Science Center, San Antonio, Texas.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Texas</region>
</placeName>
<wicri:cityArea>The Texas Liver Institute, University of Texas Health Science Center, San Antonio</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Hezode, Christophe" sort="Hezode, Christophe" uniqKey="Hezode C" first="Christophe" last="Hézode">Christophe Hézode</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Hepatology, Hôpital Henri Mondor, Créteil, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Department of Hepatology, Hôpital Henri Mondor, Créteil</wicri:regionArea>
<placeName><region type="region">Île-de-France</region>
<region type="old region">Île-de-France</region>
<settlement type="city">Créteil</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Shafran, Stephen D" sort="Shafran, Stephen D" uniqKey="Shafran S" first="Stephen D" last="Shafran">Stephen D. Shafran</name>
<affiliation wicri:level="1"><nlm:affiliation>Division of Infectious Diseases, University of Alberta, Edmonton, Alberta, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Division of Infectious Diseases, University of Alberta, Edmonton, Alberta</wicri:regionArea>
<wicri:noRegion>Alberta</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Ramji, Alnoor" sort="Ramji, Alnoor" uniqKey="Ramji A" first="Alnoor" last="Ramji">Alnoor Ramji</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Gastroenterology, University of British Columbia, Vancouver, British Columbia, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Department of Gastroenterology, University of British Columbia, Vancouver, British Columbia</wicri:regionArea>
<wicri:noRegion>British Columbia</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Tatum, Harvey A" sort="Tatum, Harvey A" uniqKey="Tatum H" first="Harvey A" last="Tatum">Harvey A. Tatum</name>
<affiliation wicri:level="2"><nlm:affiliation>Options Health Research, Tulsa, Oklahoma.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Oklahoma</region>
</placeName>
<wicri:cityArea>Options Health Research, Tulsa</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Taliani, Gloria" sort="Taliani, Gloria" uniqKey="Taliani G" first="Gloria" last="Taliani">Gloria Taliani</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Clinical Medicine, Sapienza Università di Roma, Rome, Italy.</nlm:affiliation>
<country xml:lang="fr">Italie</country>
<wicri:regionArea>Department of Clinical Medicine, Sapienza Università di Roma, Rome</wicri:regionArea>
<placeName><settlement type="city">Rome</settlement>
<region nuts="2">Latium</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Tran, Albert" sort="Tran, Albert" uniqKey="Tran A" first="Albert" last="Tran">Albert Tran</name>
<affiliation wicri:level="3"><nlm:affiliation>Faculty of Medicine, Hôpital De L'Archet 2, Nice, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Faculty of Medicine, Hôpital De L'Archet 2, Nice</wicri:regionArea>
<placeName><region type="region">Provence-Alpes-Côte d'Azur</region>
<region type="old region">Provence-Alpes-Côte d'Azur</region>
<settlement type="city">Nice</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Brunetto, Maurizia R" sort="Brunetto, Maurizia R" uniqKey="Brunetto M" first="Maurizia R" last="Brunetto">Maurizia R. Brunetto</name>
<affiliation wicri:level="3"><nlm:affiliation>Hepatology Unit, University Hospital, Pisa, Italy.</nlm:affiliation>
<country xml:lang="fr">Italie</country>
<wicri:regionArea>Hepatology Unit, University Hospital, Pisa</wicri:regionArea>
<placeName><settlement type="city">Pise</settlement>
<region nuts="2">Toscane</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Zaltron, Serena" sort="Zaltron, Serena" uniqKey="Zaltron S" first="Serena" last="Zaltron">Serena Zaltron</name>
<affiliation wicri:level="1"><nlm:affiliation>University Division of Infectious and Tropical Diseases, Azienda Ospedaliera Spedali Civili, Brescia, Italy.</nlm:affiliation>
<country xml:lang="fr">Italie</country>
<wicri:regionArea>University Division of Infectious and Tropical Diseases, Azienda Ospedaliera Spedali Civili, Brescia</wicri:regionArea>
<wicri:noRegion>Brescia</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Strasser, Simone I" sort="Strasser, Simone I" uniqKey="Strasser S" first="Simone I" last="Strasser">Simone I. Strasser</name>
<affiliation wicri:level="3"><nlm:affiliation>AW Morrow Gastroenterology and Liver Centre, Royal Prince Alfred Hospital, Sydney, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>AW Morrow Gastroenterology and Liver Centre, Royal Prince Alfred Hospital, Sydney</wicri:regionArea>
<placeName><settlement type="city">Sydney</settlement>
<region type="état">Nouvelle-Galles du Sud</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Weis, Nina" sort="Weis, Nina" uniqKey="Weis N" first="Nina" last="Weis">Nina Weis</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Infectious Diseases, Copenhagen University Hospital, Hvidovre, Denmark.</nlm:affiliation>
<country xml:lang="fr">Danemark</country>
<wicri:regionArea>Department of Infectious Diseases, Copenhagen University Hospital, Hvidovre</wicri:regionArea>
<wicri:noRegion>Hvidovre</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Ghesquiere, Wayne" sort="Ghesquiere, Wayne" uniqKey="Ghesquiere W" first="Wayne" last="Ghesquiere">Wayne Ghesquiere</name>
<affiliation wicri:level="1"><nlm:affiliation>Vancouver Island Health Authority and University of British Columbia, Victoria, British Columbia, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Vancouver Island Health Authority and University of British Columbia, Victoria, British Columbia</wicri:regionArea>
<wicri:noRegion>British Columbia</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Lee, Samuel S" sort="Lee, Samuel S" uniqKey="Lee S" first="Samuel S" last="Lee">Samuel S. Lee</name>
<affiliation wicri:level="4"><nlm:affiliation>Liver Unit, University of Calgary, Calgary, Alberta, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Liver Unit, University of Calgary, Calgary, Alberta</wicri:regionArea>
<orgName type="university">Université de Calgary</orgName>
<placeName><settlement type="city">Calgary</settlement>
<region type="state">Alberta</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Larrey, Dominique" sort="Larrey, Dominique" uniqKey="Larrey D" first="Dominique" last="Larrey">Dominique Larrey</name>
<affiliation wicri:level="3"><nlm:affiliation>Département d'Hépato-Gastroentérologie et Transplantation, Hôpital Saint Eloi, Montpellier, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Département d'Hépato-Gastroentérologie et Transplantation, Hôpital Saint Eloi, Montpellier</wicri:regionArea>
<placeName><region type="region">Occitanie (région administrative)</region>
<region type="old region">Languedoc-Roussillon</region>
<settlement type="city">Montpellier</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Pol, Stanislas" sort="Pol, Stanislas" uniqKey="Pol S" first="Stanislas" last="Pol">Stanislas Pol</name>
<affiliation wicri:level="4"><nlm:affiliation>Université Paris Descartes, Unité d'Hépatologie, Hôpital Cochin, Paris, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Université Paris Descartes, Unité d'Hépatologie, Hôpital Cochin, Paris</wicri:regionArea>
<placeName><region type="region">Île-de-France</region>
<region type="old region">Île-de-France</region>
<settlement type="city">Paris</settlement>
<settlement type="city">Paris</settlement>
</placeName>
<orgName type="university">Université Paris-Descartes</orgName>
</affiliation>
</author>
<author><name sortKey="Harley, Hugh" sort="Harley, Hugh" uniqKey="Harley H" first="Hugh" last="Harley">Hugh Harley</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Gastroenterology and Hepatology, Royal Adelaide Hospital and University of Adelaide, Adelaide, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Department of Gastroenterology and Hepatology, Royal Adelaide Hospital and University of Adelaide, Adelaide</wicri:regionArea>
<wicri:noRegion>Adelaide</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="George, Jacob" sort="George, Jacob" uniqKey="George J" first="Jacob" last="George">Jacob George</name>
<affiliation wicri:level="3"><nlm:affiliation>Storr Liver Unit, Westmead Millennium Institute, University of Sydney and Westmead Hospital, Sydney, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Storr Liver Unit, Westmead Millennium Institute, University of Sydney and Westmead Hospital, Sydney</wicri:regionArea>
<placeName><settlement type="city">Sydney</settlement>
<region type="état">Nouvelle-Galles du Sud</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Fung, Scott K" sort="Fung, Scott K" uniqKey="Fung S" first="Scott K" last="Fung">Scott K. Fung</name>
<affiliation wicri:level="1"><nlm:affiliation>Divisions of Gastroenterology and General Internal Medicine, Toronto General Hospital, Toronto, Ontario, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Divisions of Gastroenterology and General Internal Medicine, Toronto General Hospital, Toronto, Ontario</wicri:regionArea>
<wicri:noRegion>Ontario</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="De Ledinghen, Victor" sort="De Ledinghen, Victor" uniqKey="De Ledinghen V" first="Victor" last="De Lédinghen">Victor De Lédinghen</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Hepatology and Gastroenterology, Hôpital Haut-Lévêque, Pessac, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Department of Hepatology and Gastroenterology, Hôpital Haut-Lévêque, Pessac</wicri:regionArea>
<wicri:noRegion>Pessac</wicri:noRegion>
<wicri:noRegion>Pessac</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Hagens, Peggy" sort="Hagens, Peggy" uniqKey="Hagens P" first="Peggy" last="Hagens">Peggy Hagens</name>
<affiliation wicri:level="1"><nlm:affiliation>Research and Development, Bristol-Myers Squibb, Braine-l'Alleud, Belgium.</nlm:affiliation>
<country xml:lang="fr">Belgique</country>
<wicri:regionArea>Research and Development, Bristol-Myers Squibb, Braine-l'Alleud</wicri:regionArea>
<wicri:noRegion>Braine-l'Alleud</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Mcphee, Fiona" sort="Mcphee, Fiona" uniqKey="Mcphee F" first="Fiona" last="Mcphee">Fiona Mcphee</name>
<affiliation wicri:level="2"><nlm:affiliation>Research and Development, Bristol-Myers Squibb, Wallingford, Connecticut.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Connecticut</region>
</placeName>
<wicri:cityArea>Research and Development, Bristol-Myers Squibb, Wallingford</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Hernandez, Dennis" sort="Hernandez, Dennis" uniqKey="Hernandez D" first="Dennis" last="Hernandez">Dennis Hernandez</name>
<affiliation wicri:level="2"><nlm:affiliation>Research and Development, Bristol-Myers Squibb, Wallingford, Connecticut.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Connecticut</region>
</placeName>
<wicri:cityArea>Research and Development, Bristol-Myers Squibb, Wallingford</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Cohen, David" sort="Cohen, David" uniqKey="Cohen D" first="David" last="Cohen">David Cohen</name>
<affiliation wicri:level="2"><nlm:affiliation>Research and Development, Bristol-Myers Squibb, Wallingford, Connecticut.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Connecticut</region>
</placeName>
<wicri:cityArea>Research and Development, Bristol-Myers Squibb, Wallingford</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Cooney, Elizabeth" sort="Cooney, Elizabeth" uniqKey="Cooney E" first="Elizabeth" last="Cooney">Elizabeth Cooney</name>
<affiliation wicri:level="2"><nlm:affiliation>Research and Development, Bristol-Myers Squibb, Wallingford, Connecticut.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Connecticut</region>
</placeName>
<wicri:cityArea>Research and Development, Bristol-Myers Squibb, Wallingford</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Noviello, Stephanie" sort="Noviello, Stephanie" uniqKey="Noviello S" first="Stephanie" last="Noviello">Stephanie Noviello</name>
<affiliation wicri:level="2"><nlm:affiliation>Research and Development, Bristol-Myers Squibb, Princeton, New Jersey.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">New Jersey</region>
</placeName>
<wicri:cityArea>Research and Development, Bristol-Myers Squibb, Princeton</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Hughes, Eric A" sort="Hughes, Eric A" uniqKey="Hughes E" first="Eric A" last="Hughes">Eric A. Hughes</name>
<affiliation wicri:level="2"><nlm:affiliation>Research and Development, Bristol-Myers Squibb, Princeton, New Jersey.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">New Jersey</region>
</placeName>
<wicri:cityArea>Research and Development, Bristol-Myers Squibb, Princeton</wicri:cityArea>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2015">2015</date>
<idno type="RBID">pubmed:25311593</idno>
<idno type="pmid">25311593</idno>
<idno type="doi">10.1053/j.gastro.2014.10.007</idno>
<idno type="wicri:Area/PubMed/Corpus">003078</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">003078</idno>
<idno type="wicri:Area/PubMed/Curation">002F97</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">002F97</idno>
<idno type="wicri:Area/PubMed/Checkpoint">002F97</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">002F97</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Daclatasvir plus peginterferon and ribavirin is noninferior to peginterferon and ribavirin alone, and reduces the duration of treatment for HCV genotype 2 or 3 infection.</title>
<author><name sortKey="Dore, Gregory J" sort="Dore, Gregory J" uniqKey="Dore G" first="Gregory J" last="Dore">Gregory J. Dore</name>
<affiliation wicri:level="3"><nlm:affiliation>Kirby Institute, University of New South Wales and St Vincent's Hospital, Sydney, Australia. Electronic address: gdore@kirby.unsw.edu.au.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Kirby Institute, University of New South Wales and St Vincent's Hospital, Sydney</wicri:regionArea>
<placeName><settlement type="city">Sydney</settlement>
<region type="état">Nouvelle-Galles du Sud</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Lawitz, Eric" sort="Lawitz, Eric" uniqKey="Lawitz E" first="Eric" last="Lawitz">Eric Lawitz</name>
<affiliation wicri:level="2"><nlm:affiliation>The Texas Liver Institute, University of Texas Health Science Center, San Antonio, Texas.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Texas</region>
</placeName>
<wicri:cityArea>The Texas Liver Institute, University of Texas Health Science Center, San Antonio</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Hezode, Christophe" sort="Hezode, Christophe" uniqKey="Hezode C" first="Christophe" last="Hézode">Christophe Hézode</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Hepatology, Hôpital Henri Mondor, Créteil, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Department of Hepatology, Hôpital Henri Mondor, Créteil</wicri:regionArea>
<placeName><region type="region">Île-de-France</region>
<region type="old region">Île-de-France</region>
<settlement type="city">Créteil</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Shafran, Stephen D" sort="Shafran, Stephen D" uniqKey="Shafran S" first="Stephen D" last="Shafran">Stephen D. Shafran</name>
<affiliation wicri:level="1"><nlm:affiliation>Division of Infectious Diseases, University of Alberta, Edmonton, Alberta, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Division of Infectious Diseases, University of Alberta, Edmonton, Alberta</wicri:regionArea>
<wicri:noRegion>Alberta</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Ramji, Alnoor" sort="Ramji, Alnoor" uniqKey="Ramji A" first="Alnoor" last="Ramji">Alnoor Ramji</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Gastroenterology, University of British Columbia, Vancouver, British Columbia, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Department of Gastroenterology, University of British Columbia, Vancouver, British Columbia</wicri:regionArea>
<wicri:noRegion>British Columbia</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Tatum, Harvey A" sort="Tatum, Harvey A" uniqKey="Tatum H" first="Harvey A" last="Tatum">Harvey A. Tatum</name>
<affiliation wicri:level="2"><nlm:affiliation>Options Health Research, Tulsa, Oklahoma.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Oklahoma</region>
</placeName>
<wicri:cityArea>Options Health Research, Tulsa</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Taliani, Gloria" sort="Taliani, Gloria" uniqKey="Taliani G" first="Gloria" last="Taliani">Gloria Taliani</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Clinical Medicine, Sapienza Università di Roma, Rome, Italy.</nlm:affiliation>
<country xml:lang="fr">Italie</country>
<wicri:regionArea>Department of Clinical Medicine, Sapienza Università di Roma, Rome</wicri:regionArea>
<placeName><settlement type="city">Rome</settlement>
<region nuts="2">Latium</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Tran, Albert" sort="Tran, Albert" uniqKey="Tran A" first="Albert" last="Tran">Albert Tran</name>
<affiliation wicri:level="3"><nlm:affiliation>Faculty of Medicine, Hôpital De L'Archet 2, Nice, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Faculty of Medicine, Hôpital De L'Archet 2, Nice</wicri:regionArea>
<placeName><region type="region">Provence-Alpes-Côte d'Azur</region>
<region type="old region">Provence-Alpes-Côte d'Azur</region>
<settlement type="city">Nice</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Brunetto, Maurizia R" sort="Brunetto, Maurizia R" uniqKey="Brunetto M" first="Maurizia R" last="Brunetto">Maurizia R. Brunetto</name>
<affiliation wicri:level="3"><nlm:affiliation>Hepatology Unit, University Hospital, Pisa, Italy.</nlm:affiliation>
<country xml:lang="fr">Italie</country>
<wicri:regionArea>Hepatology Unit, University Hospital, Pisa</wicri:regionArea>
<placeName><settlement type="city">Pise</settlement>
<region nuts="2">Toscane</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Zaltron, Serena" sort="Zaltron, Serena" uniqKey="Zaltron S" first="Serena" last="Zaltron">Serena Zaltron</name>
<affiliation wicri:level="1"><nlm:affiliation>University Division of Infectious and Tropical Diseases, Azienda Ospedaliera Spedali Civili, Brescia, Italy.</nlm:affiliation>
<country xml:lang="fr">Italie</country>
<wicri:regionArea>University Division of Infectious and Tropical Diseases, Azienda Ospedaliera Spedali Civili, Brescia</wicri:regionArea>
<wicri:noRegion>Brescia</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Strasser, Simone I" sort="Strasser, Simone I" uniqKey="Strasser S" first="Simone I" last="Strasser">Simone I. Strasser</name>
<affiliation wicri:level="3"><nlm:affiliation>AW Morrow Gastroenterology and Liver Centre, Royal Prince Alfred Hospital, Sydney, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>AW Morrow Gastroenterology and Liver Centre, Royal Prince Alfred Hospital, Sydney</wicri:regionArea>
<placeName><settlement type="city">Sydney</settlement>
<region type="état">Nouvelle-Galles du Sud</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Weis, Nina" sort="Weis, Nina" uniqKey="Weis N" first="Nina" last="Weis">Nina Weis</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Infectious Diseases, Copenhagen University Hospital, Hvidovre, Denmark.</nlm:affiliation>
<country xml:lang="fr">Danemark</country>
<wicri:regionArea>Department of Infectious Diseases, Copenhagen University Hospital, Hvidovre</wicri:regionArea>
<wicri:noRegion>Hvidovre</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Ghesquiere, Wayne" sort="Ghesquiere, Wayne" uniqKey="Ghesquiere W" first="Wayne" last="Ghesquiere">Wayne Ghesquiere</name>
<affiliation wicri:level="1"><nlm:affiliation>Vancouver Island Health Authority and University of British Columbia, Victoria, British Columbia, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Vancouver Island Health Authority and University of British Columbia, Victoria, British Columbia</wicri:regionArea>
<wicri:noRegion>British Columbia</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Lee, Samuel S" sort="Lee, Samuel S" uniqKey="Lee S" first="Samuel S" last="Lee">Samuel S. Lee</name>
<affiliation wicri:level="4"><nlm:affiliation>Liver Unit, University of Calgary, Calgary, Alberta, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Liver Unit, University of Calgary, Calgary, Alberta</wicri:regionArea>
<orgName type="university">Université de Calgary</orgName>
<placeName><settlement type="city">Calgary</settlement>
<region type="state">Alberta</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Larrey, Dominique" sort="Larrey, Dominique" uniqKey="Larrey D" first="Dominique" last="Larrey">Dominique Larrey</name>
<affiliation wicri:level="3"><nlm:affiliation>Département d'Hépato-Gastroentérologie et Transplantation, Hôpital Saint Eloi, Montpellier, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Département d'Hépato-Gastroentérologie et Transplantation, Hôpital Saint Eloi, Montpellier</wicri:regionArea>
<placeName><region type="region">Occitanie (région administrative)</region>
<region type="old region">Languedoc-Roussillon</region>
<settlement type="city">Montpellier</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Pol, Stanislas" sort="Pol, Stanislas" uniqKey="Pol S" first="Stanislas" last="Pol">Stanislas Pol</name>
<affiliation wicri:level="4"><nlm:affiliation>Université Paris Descartes, Unité d'Hépatologie, Hôpital Cochin, Paris, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Université Paris Descartes, Unité d'Hépatologie, Hôpital Cochin, Paris</wicri:regionArea>
<placeName><region type="region">Île-de-France</region>
<region type="old region">Île-de-France</region>
<settlement type="city">Paris</settlement>
<settlement type="city">Paris</settlement>
</placeName>
<orgName type="university">Université Paris-Descartes</orgName>
</affiliation>
</author>
<author><name sortKey="Harley, Hugh" sort="Harley, Hugh" uniqKey="Harley H" first="Hugh" last="Harley">Hugh Harley</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Gastroenterology and Hepatology, Royal Adelaide Hospital and University of Adelaide, Adelaide, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Department of Gastroenterology and Hepatology, Royal Adelaide Hospital and University of Adelaide, Adelaide</wicri:regionArea>
<wicri:noRegion>Adelaide</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="George, Jacob" sort="George, Jacob" uniqKey="George J" first="Jacob" last="George">Jacob George</name>
<affiliation wicri:level="3"><nlm:affiliation>Storr Liver Unit, Westmead Millennium Institute, University of Sydney and Westmead Hospital, Sydney, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Storr Liver Unit, Westmead Millennium Institute, University of Sydney and Westmead Hospital, Sydney</wicri:regionArea>
<placeName><settlement type="city">Sydney</settlement>
<region type="état">Nouvelle-Galles du Sud</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Fung, Scott K" sort="Fung, Scott K" uniqKey="Fung S" first="Scott K" last="Fung">Scott K. Fung</name>
<affiliation wicri:level="1"><nlm:affiliation>Divisions of Gastroenterology and General Internal Medicine, Toronto General Hospital, Toronto, Ontario, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Divisions of Gastroenterology and General Internal Medicine, Toronto General Hospital, Toronto, Ontario</wicri:regionArea>
<wicri:noRegion>Ontario</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="De Ledinghen, Victor" sort="De Ledinghen, Victor" uniqKey="De Ledinghen V" first="Victor" last="De Lédinghen">Victor De Lédinghen</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Hepatology and Gastroenterology, Hôpital Haut-Lévêque, Pessac, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Department of Hepatology and Gastroenterology, Hôpital Haut-Lévêque, Pessac</wicri:regionArea>
<wicri:noRegion>Pessac</wicri:noRegion>
<wicri:noRegion>Pessac</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Hagens, Peggy" sort="Hagens, Peggy" uniqKey="Hagens P" first="Peggy" last="Hagens">Peggy Hagens</name>
<affiliation wicri:level="1"><nlm:affiliation>Research and Development, Bristol-Myers Squibb, Braine-l'Alleud, Belgium.</nlm:affiliation>
<country xml:lang="fr">Belgique</country>
<wicri:regionArea>Research and Development, Bristol-Myers Squibb, Braine-l'Alleud</wicri:regionArea>
<wicri:noRegion>Braine-l'Alleud</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Mcphee, Fiona" sort="Mcphee, Fiona" uniqKey="Mcphee F" first="Fiona" last="Mcphee">Fiona Mcphee</name>
<affiliation wicri:level="2"><nlm:affiliation>Research and Development, Bristol-Myers Squibb, Wallingford, Connecticut.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Connecticut</region>
</placeName>
<wicri:cityArea>Research and Development, Bristol-Myers Squibb, Wallingford</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Hernandez, Dennis" sort="Hernandez, Dennis" uniqKey="Hernandez D" first="Dennis" last="Hernandez">Dennis Hernandez</name>
<affiliation wicri:level="2"><nlm:affiliation>Research and Development, Bristol-Myers Squibb, Wallingford, Connecticut.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Connecticut</region>
</placeName>
<wicri:cityArea>Research and Development, Bristol-Myers Squibb, Wallingford</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Cohen, David" sort="Cohen, David" uniqKey="Cohen D" first="David" last="Cohen">David Cohen</name>
<affiliation wicri:level="2"><nlm:affiliation>Research and Development, Bristol-Myers Squibb, Wallingford, Connecticut.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Connecticut</region>
</placeName>
<wicri:cityArea>Research and Development, Bristol-Myers Squibb, Wallingford</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Cooney, Elizabeth" sort="Cooney, Elizabeth" uniqKey="Cooney E" first="Elizabeth" last="Cooney">Elizabeth Cooney</name>
<affiliation wicri:level="2"><nlm:affiliation>Research and Development, Bristol-Myers Squibb, Wallingford, Connecticut.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Connecticut</region>
</placeName>
<wicri:cityArea>Research and Development, Bristol-Myers Squibb, Wallingford</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Noviello, Stephanie" sort="Noviello, Stephanie" uniqKey="Noviello S" first="Stephanie" last="Noviello">Stephanie Noviello</name>
<affiliation wicri:level="2"><nlm:affiliation>Research and Development, Bristol-Myers Squibb, Princeton, New Jersey.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">New Jersey</region>
</placeName>
<wicri:cityArea>Research and Development, Bristol-Myers Squibb, Princeton</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Hughes, Eric A" sort="Hughes, Eric A" uniqKey="Hughes E" first="Eric A" last="Hughes">Eric A. Hughes</name>
<affiliation wicri:level="2"><nlm:affiliation>Research and Development, Bristol-Myers Squibb, Princeton, New Jersey.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">New Jersey</region>
</placeName>
<wicri:cityArea>Research and Development, Bristol-Myers Squibb, Princeton</wicri:cityArea>
</affiliation>
</author>
</analytic>
<series><title level="j">Gastroenterology</title>
<idno type="eISSN">1528-0012</idno>
<imprint><date when="2015" type="published">2015</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adolescent</term>
<term>Adult</term>
<term>Aged</term>
<term>Antiviral Agents (therapeutic use)</term>
<term>Double-Blind Method</term>
<term>Drug Therapy, Combination</term>
<term>Female</term>
<term>Genotype</term>
<term>Hepacivirus (classification)</term>
<term>Hepatitis C, Chronic (drug therapy)</term>
<term>Hepatitis C, Chronic (virology)</term>
<term>Humans</term>
<term>Imidazoles (administration & dosage)</term>
<term>Imidazoles (adverse effects)</term>
<term>Interferon-alpha (administration & dosage)</term>
<term>Interferon-alpha (adverse effects)</term>
<term>Interferon-alpha (therapeutic use)</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Polyethylene Glycols (administration & dosage)</term>
<term>Polyethylene Glycols (adverse effects)</term>
<term>Polyethylene Glycols (therapeutic use)</term>
<term>RNA, Viral (analysis)</term>
<term>Recombinant Proteins (administration & dosage)</term>
<term>Recombinant Proteins (adverse effects)</term>
<term>Recombinant Proteins (therapeutic use)</term>
<term>Ribavirin (administration & dosage)</term>
<term>Ribavirin (adverse effects)</term>
<term>Ribavirin (therapeutic use)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>ARN viral (analyse)</term>
<term>Adolescent</term>
<term>Adulte</term>
<term>Adulte d'âge moyen</term>
<term>Antiviraux (usage thérapeutique)</term>
<term>Association de médicaments</term>
<term>Femelle</term>
<term>Génotype</term>
<term>Hepacivirus ()</term>
<term>Humains</term>
<term>Hépatite C chronique (traitement médicamenteux)</term>
<term>Hépatite C chronique (virologie)</term>
<term>Imidazoles (administration et posologie)</term>
<term>Imidazoles (effets indésirables)</term>
<term>Interféron alpha (administration et posologie)</term>
<term>Interféron alpha (effets indésirables)</term>
<term>Interféron alpha (usage thérapeutique)</term>
<term>Mâle</term>
<term>Méthode en double aveugle</term>
<term>Polyéthylène glycols (administration et posologie)</term>
<term>Polyéthylène glycols (effets indésirables)</term>
<term>Polyéthylène glycols (usage thérapeutique)</term>
<term>Protéines recombinantes (administration et posologie)</term>
<term>Protéines recombinantes (effets indésirables)</term>
<term>Protéines recombinantes (usage thérapeutique)</term>
<term>Ribavirine (administration et posologie)</term>
<term>Ribavirine (effets indésirables)</term>
<term>Ribavirine (usage thérapeutique)</term>
<term>Sujet âgé</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Imidazoles</term>
<term>Interferon-alpha</term>
<term>Polyethylene Glycols</term>
<term>Recombinant Proteins</term>
<term>Ribavirin</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Imidazoles</term>
<term>Interferon-alpha</term>
<term>Polyethylene Glycols</term>
<term>Recombinant Proteins</term>
<term>Ribavirin</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="analysis" xml:lang="en"><term>RNA, Viral</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiviral Agents</term>
<term>Interferon-alpha</term>
<term>Polyethylene Glycols</term>
<term>Recombinant Proteins</term>
<term>Ribavirin</term>
</keywords>
<keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Imidazoles</term>
<term>Interféron alpha</term>
<term>Polyéthylène glycols</term>
<term>Protéines recombinantes</term>
<term>Ribavirine</term>
</keywords>
<keywords scheme="MESH" qualifier="analyse" xml:lang="fr"><term>ARN viral</term>
</keywords>
<keywords scheme="MESH" qualifier="classification" xml:lang="en"><term>Hepacivirus</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Hepatitis C, Chronic</term>
</keywords>
<keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Imidazoles</term>
<term>Interféron alpha</term>
<term>Polyéthylène glycols</term>
<term>Protéines recombinantes</term>
<term>Ribavirine</term>
</keywords>
<keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Hépatite C chronique</term>
</keywords>
<keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Antiviraux</term>
<term>Interféron alpha</term>
<term>Polyéthylène glycols</term>
<term>Protéines recombinantes</term>
<term>Ribavirine</term>
</keywords>
<keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Hépatite C chronique</term>
</keywords>
<keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Hepatitis C, Chronic</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Adolescent</term>
<term>Adult</term>
<term>Aged</term>
<term>Double-Blind Method</term>
<term>Drug Therapy, Combination</term>
<term>Female</term>
<term>Genotype</term>
<term>Humans</term>
<term>Male</term>
<term>Middle Aged</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Adolescent</term>
<term>Adulte</term>
<term>Adulte d'âge moyen</term>
<term>Association de médicaments</term>
<term>Femelle</term>
<term>Génotype</term>
<term>Hepacivirus</term>
<term>Humains</term>
<term>Mâle</term>
<term>Méthode en double aveugle</term>
<term>Sujet âgé</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Twenty-four weeks of treatment with peginterferon and ribavirin for chronic hepatitis C virus (HCV) genotype 2 or 3 infection produces a sustained virologic response (SVR) in 70%-80% of patients. We performed a randomized, double-blind, phase 2b study to assess whether adding daclatasvir, a nonstructural protein 5A (NS5A) inhibitor that is active against these genotypes, improves efficacy and shortens therapy.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">25311593</PMID>
<DateCreated><Year>2015</Year>
<Month>01</Month>
<Day>24</Day>
</DateCreated>
<DateCompleted><Year>2015</Year>
<Month>03</Month>
<Day>24</Day>
</DateCompleted>
<DateRevised><Year>2016</Year>
<Month>11</Month>
<Day>25</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1528-0012</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>148</Volume>
<Issue>2</Issue>
<PubDate><Year>2015</Year>
<Month>Feb</Month>
</PubDate>
</JournalIssue>
<Title>Gastroenterology</Title>
<ISOAbbreviation>Gastroenterology</ISOAbbreviation>
</Journal>
<ArticleTitle>Daclatasvir plus peginterferon and ribavirin is noninferior to peginterferon and ribavirin alone, and reduces the duration of treatment for HCV genotype 2 or 3 infection.</ArticleTitle>
<Pagination><MedlinePgn>355-366.e1</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1053/j.gastro.2014.10.007</ELocationID>
<ELocationID EIdType="pii" ValidYN="Y">S0016-5085(14)01206-2</ELocationID>
<Abstract><AbstractText Label="BACKGROUND & AIMS" NlmCategory="OBJECTIVE">Twenty-four weeks of treatment with peginterferon and ribavirin for chronic hepatitis C virus (HCV) genotype 2 or 3 infection produces a sustained virologic response (SVR) in 70%-80% of patients. We performed a randomized, double-blind, phase 2b study to assess whether adding daclatasvir, a nonstructural protein 5A (NS5A) inhibitor that is active against these genotypes, improves efficacy and shortens therapy.</AbstractText>
<AbstractText Label="METHODS" NlmCategory="METHODS">Patients with HCV genotype 2 or 3 infection (n = 151), enrolled at research centers in North America, Europe, or Australia, were assigned randomly to groups given 12 or 16 weeks of daclatasvir (60 mg once daily), or 24 weeks of placebo, each combined with peginterferon alfa-2a and ribavirin. Treatment was extended to 24 weeks for recipients of daclatasvir who did not meet the criteria for early virologic response. The primary end point was SVR at 24 weeks after treatment (SVR24).</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">Baseline characteristics were similar among patients within each HCV genotype group. However, the 80 patients with HCV genotype 3, compared with the 71 patients with HCV genotype 2, were younger (mean age, 45 vs 53 y, respectively), and a larger proportion had cirrhosis (23% vs 1%, respectively). Among patients with HCV genotype 2 infection, an SVR24 was achieved by 83%, 83%, and 63% of those in the daclatasvir 12-week group, the daclatasvir 16-week group, or the placebo group, respectively; among patients with HCV genotype 3 infection, an SVR24 was achieved by 69%, 67%, and 59% of patients in these groups, respectively. Differences between genotypes largely were attributable to the higher frequency of post-treatment relapse among patients infected with HCV genotype 3. In both daclatasvir arms for both HCV genotypes, the lower bound of the 80% confidence interval of the difference in SVR24 rates between the daclatasvir and placebo arms was above -20%, establishing noninferiority. Safety findings were similar among groups, and were typical of those expected from peginterferon alfa and ribavirin therapy.</AbstractText>
<AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Twelve or 16 weeks of treatment with daclatasvir, in combination with peginterferon alfa-2a and ribavirin, is a well tolerated and effective therapy for patients with HCV genotype 2 or 3 infections. Daclatasvir-containing regimens could reduce the duration of therapy for these patients. Clinicaltrials.gov number: NCT01257204.</AbstractText>
<CopyrightInformation>Copyright © 2015 AGA Institute. Published by Elsevier Inc. All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Dore</LastName>
<ForeName>Gregory J</ForeName>
<Initials>GJ</Initials>
<AffiliationInfo><Affiliation>Kirby Institute, University of New South Wales and St Vincent's Hospital, Sydney, Australia. Electronic address: gdore@kirby.unsw.edu.au.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Lawitz</LastName>
<ForeName>Eric</ForeName>
<Initials>E</Initials>
<AffiliationInfo><Affiliation>The Texas Liver Institute, University of Texas Health Science Center, San Antonio, Texas.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Hézode</LastName>
<ForeName>Christophe</ForeName>
<Initials>C</Initials>
<AffiliationInfo><Affiliation>Department of Hepatology, Hôpital Henri Mondor, Créteil, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Shafran</LastName>
<ForeName>Stephen D</ForeName>
<Initials>SD</Initials>
<AffiliationInfo><Affiliation>Division of Infectious Diseases, University of Alberta, Edmonton, Alberta, Canada.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Ramji</LastName>
<ForeName>Alnoor</ForeName>
<Initials>A</Initials>
<AffiliationInfo><Affiliation>Department of Gastroenterology, University of British Columbia, Vancouver, British Columbia, Canada.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Tatum</LastName>
<ForeName>Harvey A</ForeName>
<Initials>HA</Initials>
<AffiliationInfo><Affiliation>Options Health Research, Tulsa, Oklahoma.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Taliani</LastName>
<ForeName>Gloria</ForeName>
<Initials>G</Initials>
<AffiliationInfo><Affiliation>Department of Clinical Medicine, Sapienza Università di Roma, Rome, Italy.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Tran</LastName>
<ForeName>Albert</ForeName>
<Initials>A</Initials>
<AffiliationInfo><Affiliation>Faculty of Medicine, Hôpital De L'Archet 2, Nice, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Brunetto</LastName>
<ForeName>Maurizia R</ForeName>
<Initials>MR</Initials>
<AffiliationInfo><Affiliation>Hepatology Unit, University Hospital, Pisa, Italy.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Zaltron</LastName>
<ForeName>Serena</ForeName>
<Initials>S</Initials>
<AffiliationInfo><Affiliation>University Division of Infectious and Tropical Diseases, Azienda Ospedaliera Spedali Civili, Brescia, Italy.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Strasser</LastName>
<ForeName>Simone I</ForeName>
<Initials>SI</Initials>
<AffiliationInfo><Affiliation>AW Morrow Gastroenterology and Liver Centre, Royal Prince Alfred Hospital, Sydney, Australia.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Weis</LastName>
<ForeName>Nina</ForeName>
<Initials>N</Initials>
<AffiliationInfo><Affiliation>Department of Infectious Diseases, Copenhagen University Hospital, Hvidovre, Denmark.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Ghesquiere</LastName>
<ForeName>Wayne</ForeName>
<Initials>W</Initials>
<AffiliationInfo><Affiliation>Vancouver Island Health Authority and University of British Columbia, Victoria, British Columbia, Canada.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Lee</LastName>
<ForeName>Samuel S</ForeName>
<Initials>SS</Initials>
<AffiliationInfo><Affiliation>Liver Unit, University of Calgary, Calgary, Alberta, Canada.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Larrey</LastName>
<ForeName>Dominique</ForeName>
<Initials>D</Initials>
<AffiliationInfo><Affiliation>Département d'Hépato-Gastroentérologie et Transplantation, Hôpital Saint Eloi, Montpellier, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Pol</LastName>
<ForeName>Stanislas</ForeName>
<Initials>S</Initials>
<AffiliationInfo><Affiliation>Université Paris Descartes, Unité d'Hépatologie, Hôpital Cochin, Paris, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Harley</LastName>
<ForeName>Hugh</ForeName>
<Initials>H</Initials>
<AffiliationInfo><Affiliation>Department of Gastroenterology and Hepatology, Royal Adelaide Hospital and University of Adelaide, Adelaide, Australia.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>George</LastName>
<ForeName>Jacob</ForeName>
<Initials>J</Initials>
<AffiliationInfo><Affiliation>Storr Liver Unit, Westmead Millennium Institute, University of Sydney and Westmead Hospital, Sydney, Australia.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Fung</LastName>
<ForeName>Scott K</ForeName>
<Initials>SK</Initials>
<AffiliationInfo><Affiliation>Divisions of Gastroenterology and General Internal Medicine, Toronto General Hospital, Toronto, Ontario, Canada.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>de Lédinghen</LastName>
<ForeName>Victor</ForeName>
<Initials>V</Initials>
<AffiliationInfo><Affiliation>Department of Hepatology and Gastroenterology, Hôpital Haut-Lévêque, Pessac, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Hagens</LastName>
<ForeName>Peggy</ForeName>
<Initials>P</Initials>
<AffiliationInfo><Affiliation>Research and Development, Bristol-Myers Squibb, Braine-l'Alleud, Belgium.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>McPhee</LastName>
<ForeName>Fiona</ForeName>
<Initials>F</Initials>
<AffiliationInfo><Affiliation>Research and Development, Bristol-Myers Squibb, Wallingford, Connecticut.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Hernandez</LastName>
<ForeName>Dennis</ForeName>
<Initials>D</Initials>
<AffiliationInfo><Affiliation>Research and Development, Bristol-Myers Squibb, Wallingford, Connecticut.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Cohen</LastName>
<ForeName>David</ForeName>
<Initials>D</Initials>
<AffiliationInfo><Affiliation>Research and Development, Bristol-Myers Squibb, Wallingford, Connecticut.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Cooney</LastName>
<ForeName>Elizabeth</ForeName>
<Initials>E</Initials>
<AffiliationInfo><Affiliation>Research and Development, Bristol-Myers Squibb, Wallingford, Connecticut.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Noviello</LastName>
<ForeName>Stephanie</ForeName>
<Initials>S</Initials>
<AffiliationInfo><Affiliation>Research and Development, Bristol-Myers Squibb, Princeton, New Jersey.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Hughes</LastName>
<ForeName>Eric A</ForeName>
<Initials>EA</Initials>
<AffiliationInfo><Affiliation>Research and Development, Bristol-Myers Squibb, Princeton, New Jersey.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName>
<AccessionNumberList><AccessionNumber>NCT01257204</AccessionNumber>
</AccessionNumberList>
</DataBank>
</DataBankList>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D016449">Randomized Controlled Trial</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2014</Year>
<Month>10</Month>
<Day>13</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>United States</Country>
<MedlineTA>Gastroenterology</MedlineTA>
<NlmUniqueID>0374630</NlmUniqueID>
<ISSNLinking>0016-5085</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C549273">BMS-790052</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D007093">Imidazoles</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D016898">Interferon-alpha</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D012367">RNA, Viral</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D011994">Recombinant Proteins</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>30IQX730WE</RegistryNumber>
<NameOfSubstance UI="D011092">Polyethylene Glycols</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>49717AWG6K</RegistryNumber>
<NameOfSubstance UI="D012254">Ribavirin</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>Q46947FE7K</RegistryNumber>
<NameOfSubstance UI="C100416">peginterferon alfa-2a</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>AIM</CitationSubset>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016174" MajorTopicYN="N">Hepacivirus</DescriptorName>
<QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D019698" MajorTopicYN="N">Hepatitis C, Chronic</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
<QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007093" MajorTopicYN="N">Imidazoles</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName>
<QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016898" MajorTopicYN="N">Interferon-alpha</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
<QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011092" MajorTopicYN="N">Polyethylene Glycols</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
<QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D012367" MajorTopicYN="N">RNA, Viral</DescriptorName>
<QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011994" MajorTopicYN="N">Recombinant Proteins</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
<QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D012254" MajorTopicYN="N">Ribavirin</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
<QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Antiviral</Keyword>
<Keyword MajorTopicYN="N">Combination Therapy</Keyword>
<Keyword MajorTopicYN="N">DAA</Keyword>
<Keyword MajorTopicYN="N">NS5A Replication Complex Inhibitor</Keyword>
</KeywordList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2013</Year>
<Month>12</Month>
<Day>13</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="revised"><Year>2014</Year>
<Month>10</Month>
<Day>03</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2014</Year>
<Month>10</Month>
<Day>06</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2014</Year>
<Month>10</Month>
<Day>15</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2014</Year>
<Month>10</Month>
<Day>15</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2015</Year>
<Month>3</Month>
<Day>25</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">25311593</ArticleId>
<ArticleId IdType="pii">S0016-5085(14)01206-2</ArticleId>
<ArticleId IdType="doi">10.1053/j.gastro.2014.10.007</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>Australie</li>
<li>Belgique</li>
<li>Canada</li>
<li>Danemark</li>
<li>France</li>
<li>Italie</li>
<li>États-Unis</li>
</country>
<region><li>Alberta</li>
<li>Connecticut</li>
<li>Languedoc-Roussillon</li>
<li>Latium</li>
<li>New Jersey</li>
<li>Nouvelle-Galles du Sud</li>
<li>Occitanie (région administrative)</li>
<li>Oklahoma</li>
<li>Provence-Alpes-Côte d'Azur</li>
<li>Texas</li>
<li>Toscane</li>
<li>Île-de-France</li>
</region>
<settlement><li>Calgary</li>
<li>Créteil</li>
<li>Montpellier</li>
<li>Nice</li>
<li>Paris</li>
<li>Pise</li>
<li>Rome</li>
<li>Sydney</li>
</settlement>
<orgName><li>Université Paris-Descartes</li>
<li>Université de Calgary</li>
</orgName>
</list>
<tree><country name="Australie"><region name="Nouvelle-Galles du Sud"><name sortKey="Dore, Gregory J" sort="Dore, Gregory J" uniqKey="Dore G" first="Gregory J" last="Dore">Gregory J. Dore</name>
</region>
<name sortKey="George, Jacob" sort="George, Jacob" uniqKey="George J" first="Jacob" last="George">Jacob George</name>
<name sortKey="Harley, Hugh" sort="Harley, Hugh" uniqKey="Harley H" first="Hugh" last="Harley">Hugh Harley</name>
<name sortKey="Strasser, Simone I" sort="Strasser, Simone I" uniqKey="Strasser S" first="Simone I" last="Strasser">Simone I. Strasser</name>
</country>
<country name="États-Unis"><region name="Texas"><name sortKey="Lawitz, Eric" sort="Lawitz, Eric" uniqKey="Lawitz E" first="Eric" last="Lawitz">Eric Lawitz</name>
</region>
<name sortKey="Cohen, David" sort="Cohen, David" uniqKey="Cohen D" first="David" last="Cohen">David Cohen</name>
<name sortKey="Cooney, Elizabeth" sort="Cooney, Elizabeth" uniqKey="Cooney E" first="Elizabeth" last="Cooney">Elizabeth Cooney</name>
<name sortKey="Hernandez, Dennis" sort="Hernandez, Dennis" uniqKey="Hernandez D" first="Dennis" last="Hernandez">Dennis Hernandez</name>
<name sortKey="Hughes, Eric A" sort="Hughes, Eric A" uniqKey="Hughes E" first="Eric A" last="Hughes">Eric A. Hughes</name>
<name sortKey="Mcphee, Fiona" sort="Mcphee, Fiona" uniqKey="Mcphee F" first="Fiona" last="Mcphee">Fiona Mcphee</name>
<name sortKey="Noviello, Stephanie" sort="Noviello, Stephanie" uniqKey="Noviello S" first="Stephanie" last="Noviello">Stephanie Noviello</name>
<name sortKey="Tatum, Harvey A" sort="Tatum, Harvey A" uniqKey="Tatum H" first="Harvey A" last="Tatum">Harvey A. Tatum</name>
</country>
<country name="France"><region name="Île-de-France"><name sortKey="Hezode, Christophe" sort="Hezode, Christophe" uniqKey="Hezode C" first="Christophe" last="Hézode">Christophe Hézode</name>
</region>
<name sortKey="De Ledinghen, Victor" sort="De Ledinghen, Victor" uniqKey="De Ledinghen V" first="Victor" last="De Lédinghen">Victor De Lédinghen</name>
<name sortKey="Larrey, Dominique" sort="Larrey, Dominique" uniqKey="Larrey D" first="Dominique" last="Larrey">Dominique Larrey</name>
<name sortKey="Pol, Stanislas" sort="Pol, Stanislas" uniqKey="Pol S" first="Stanislas" last="Pol">Stanislas Pol</name>
<name sortKey="Tran, Albert" sort="Tran, Albert" uniqKey="Tran A" first="Albert" last="Tran">Albert Tran</name>
</country>
<country name="Canada"><noRegion><name sortKey="Shafran, Stephen D" sort="Shafran, Stephen D" uniqKey="Shafran S" first="Stephen D" last="Shafran">Stephen D. Shafran</name>
</noRegion>
<name sortKey="Fung, Scott K" sort="Fung, Scott K" uniqKey="Fung S" first="Scott K" last="Fung">Scott K. Fung</name>
<name sortKey="Ghesquiere, Wayne" sort="Ghesquiere, Wayne" uniqKey="Ghesquiere W" first="Wayne" last="Ghesquiere">Wayne Ghesquiere</name>
<name sortKey="Lee, Samuel S" sort="Lee, Samuel S" uniqKey="Lee S" first="Samuel S" last="Lee">Samuel S. Lee</name>
<name sortKey="Ramji, Alnoor" sort="Ramji, Alnoor" uniqKey="Ramji A" first="Alnoor" last="Ramji">Alnoor Ramji</name>
</country>
<country name="Italie"><region name="Latium"><name sortKey="Taliani, Gloria" sort="Taliani, Gloria" uniqKey="Taliani G" first="Gloria" last="Taliani">Gloria Taliani</name>
</region>
<name sortKey="Brunetto, Maurizia R" sort="Brunetto, Maurizia R" uniqKey="Brunetto M" first="Maurizia R" last="Brunetto">Maurizia R. Brunetto</name>
<name sortKey="Zaltron, Serena" sort="Zaltron, Serena" uniqKey="Zaltron S" first="Serena" last="Zaltron">Serena Zaltron</name>
</country>
<country name="Danemark"><noRegion><name sortKey="Weis, Nina" sort="Weis, Nina" uniqKey="Weis N" first="Nina" last="Weis">Nina Weis</name>
</noRegion>
</country>
<country name="Belgique"><noRegion><name sortKey="Hagens, Peggy" sort="Hagens, Peggy" uniqKey="Hagens P" first="Peggy" last="Hagens">Peggy Hagens</name>
</noRegion>
</country>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002D47 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 002D47 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Asie |area= AustralieFrV1 |flux= PubMed |étape= Checkpoint |type= RBID |clé= pubmed:25311593 |texte= Daclatasvir plus peginterferon and ribavirin is noninferior to peginterferon and ribavirin alone, and reduces the duration of treatment for HCV genotype 2 or 3 infection. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:25311593" \ | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \ | NlmPubMed2Wicri -a AustralieFrV1
![]() | This area was generated with Dilib version V0.6.33. | ![]() |